Affiliations of authors: Department of Medica1 Oncology, University Campus Bio-Medico, Rome, Italy (GT, BV, DS); Department of Ophthalmology, University Campus Bio-Medico, Rome, Italy (DO, AL, SB)
Correspondence to: Bruno Vincenzi, MD, University Campus Bio-Medico, Rome, Via E. Longoni n. 83,00155 Rome, Italy (e-mail: b.vincenzi{at}unicampus.it).
A 58-year-old Italian woman was diagnosed in December 1997 with colon adenocarcinoma. After resection and preoperative clinical evaluation for distant metastases, the disease was classified as pT4, pN1, cM0. She received six courses of adjuvant chemotherapy with 5-fluorouracil and folinic acid, according to the Mayo Clinic schedule (1). By October 2000, the disease had progressed to the liver, and the patient was therefore treated with 12 courses of irinotecan plus bimonthly, high-dose leucovorin and bolus and continuous infusion of 5-fluorouracil (FOLFIRI regimen), after which she attained a clinical partial response. However, 5 months after chemotherapy ended, disease progressed to the liver and to the lungs. The patient was then started on second-line chemotherapy with oxaliplatin plus bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFOX 4 regimen). Restaging after 12 courses of the second-line chemotherapy showed stable disease, so we decided to stop treatment and perform follow-up examination every 3 months. Six months after the FOLFOX 4 regimen was stopped, disease progression was identified, and the patient started chemotherapy with Raltitrexed plus irinotecan. However, the patient experienced grade 3 gastrointestinal toxicity, so treatment was stopped after the second cycle. Subsequently, we decided to test the primary tumor for epidermal growth factor receptor (EGFR) expression using immunohistochemical staining. The tumor stained positive for EGFR, so we began treating the patient with immunotherapy using cetuximab, a monoclonal antibody that specifically blocks EGFR activity (2). Cetuximab at standard dosages was started, and a mild, self-limiting cutaneous acneiform eruption was evident after just 1 week.
Three weeks after beginning cetuximab treatment, the patient reported bilateral ocular discomfort, characterized by itchiness all around both eyelids, photophobia, foreign body sensation, tearing associated with exfoliated skin, oil secretions, and crusty scaling. Visual activity, intraocular pressure, and fundus were normal upon ocular examination. However, the ocular surface was characterized by a corneal transparency and mild conjunctival hyperemia (Fig. 1). This clinical presentation is typical of squamous blepharitis, a condition that is related to meibomian gland dysfunction. Any other cause of squamous blepharitis, such as immune or allergic diseases and iatrogenic etiology, was excluded, and an infective pathogen was not identified. After 1-week delay of immunotherapy and topical antibiotic therapy (macrolides), all clinical signs and symptoms of squamous blepharitis disappeared. However, 2 weeks after immunotherapy was restarted, the same ocular manifestations recurred.
|
REFERENCES
(1) Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994;330:113642.
(2) Castillo L, Etienne-Grimaldi MC, Fischel JL, Formento P, Magne N, Milano G, et al. Pharmacological background of EGFR targeting. Ann Oncol 2004;15:100712.
(3) Cunningham D, Humblet Y, Siena S, Khayat D,Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:33754.
(4) Green MR, Couchman JR. Distribution of epidermal growth factor receptors in rat tissues during embryonic skin development, hair formation, and the adult hair growth cycle. J Invest Dermatol 1984;83:11823.[CrossRef][ISI][Medline]
(5) Wu X, Rubin M, Fan Z, DeBlasio T, Soos T, Koff A, et al. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 1996;12:1397403.[ISI][Medline]
(6) Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001;144:116976.[CrossRef][ISI][Medline]
![]() |
||||
|
Oxford University Press Privacy Policy and Legal Statement |